Department of Genetic and Laboratory Medicine, Geneva University Hospitals, Switzerland; Department of Pathology and Immunology, University of Geneva, Faculty of Medicine, Geneva, Switzerland.
Int J Pharm. 2009 Nov 3;381(2):113-21. doi: 10.1016/j.ijpharm.2009.03.003. Epub 2009 Mar 19.
Cell replacement therapy is a widely discussed novel concept of medical treatment. The increased knowledge in the stem cell field, particularly pluripotent stem cells, potentially provides powerful tools for this therapeutic concept. A large number of disease characterized by the loss of functional cells are potential candidates for cell replacement therapy and, in this regards, Parkinson's disease is of particular interest. It is one of the most prevalent neurodegenerative diseases caused by the loss of dopaminergic neurons in the Substantia nigra pars compacta. Pharmacological therapies are valuable but suffer from the progressive decline of efficacy as the disease progresses. Cell therapy application has emerged about two decades ago as a valid therapeutic alternative and recent advances in stem cell research suggest that pluripotent stem cell transplantation may be a promising approach to replace degenerated neurons in Parkinson's disease. Various sources of pluripotent stem cells (PSC) currently tested in animal models of Parkinson's disease have proven their efficacy in relieving symptoms and restoring damaged brain function. This review summarizes and discusses the important challenges that actually must be solved before the first studies of PSC transplantation can be undertaken into humans.
细胞替代疗法是一种广泛讨论的新型医学治疗概念。干细胞领域知识的不断增加,特别是多能干细胞,为这一治疗概念提供了强大的工具。大量以功能性细胞丧失为特征的疾病是细胞替代治疗的潜在候选者,在这方面,帕金森病尤其受到关注。它是由黑质致密部多巴胺能神经元丧失引起的最常见的神经退行性疾病之一。药物疗法很有价值,但随着疾病的进展,其疗效逐渐下降。细胞治疗应用在大约二十年前出现,作为一种有效的治疗选择,最近干细胞研究的进展表明,多能干细胞移植可能是一种有前途的方法,可以替代帕金森病中退化的神经元。目前在帕金森病动物模型中测试的各种多能干细胞 (PSC) 已证明其在缓解症状和恢复受损大脑功能方面的有效性。这篇综述总结和讨论了在进行多能干细胞移植的人体研究之前,实际上必须解决的重要挑战。